255
Participants
Start Date
November 30, 2011
Primary Completion Date
August 31, 2021
Study Completion Date
October 31, 2021
Axitinib
Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.
Sandostatin LAR
Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity
Placebo
orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.
MD Anderson Cancer Center, Madrid
Hospital Universitario Virgen de la Victoria, Málaga
Marburg Universitätsklinikum Giessen und Marburg GmbH, Marburg
Hospital Alvaro Cunqueiro, Vigo
Hospital General Universitario de Valencia, Valencia
Azienda Ospedaliera Universitaria di Perugia, Perugia
Sapienza, Universitá di Roma, Ospedale sant'Andrea, Rome
Institut Català d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat
Hospital Central de Asturias, Oviedo
Complejo Hospitalario Univ A Coruña, A Coruña
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Universitario de Burgos, Burgos
Hospital de Donostia, Donostia / San Sebastian
Hospital Virgen de las Nieves, Granada
Hospital universitario de Leon, León
Hospital Clara Campal, Madrid
Hospital Clínico San Carlos, Madrid
Hospital Gregorio Marañón, Madrid
Hospital Univ La Paz, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Ramón y Cajal, Madrid
Hospital Univ de Salamanca, Salamanca
Hospital Marqués de Valdecilla, Santander
Hospital Universitario Virgen del Rocío, Seville
Hospital Universitario Miguel Servet, Zaragoza
Clatterbridge Cancer Centre, Bebington
Collaborators (1)
Pfizer
INDUSTRY
Grupo Espanol de Tumores Neuroendocrinos
OTHER